NutriBand (NTRB) Cash from Investing Activities (2018 - 2025)
NutriBand (NTRB) posted Cash from Investing Activities of -$5324.0 for Q2 2025, up 88.66% sequentially from -$46958.0 in Q4 2024, and up 14.06% YoY from -$4667.7 in Q2 2024.
NutriBand (NTRB) Cash from Investing Activities (2018 - 2025) Analysis & Trends
NutriBand has reported Cash from Investing Activities for 6 years, with the latest figure at -$5324.0 in Q2 2025.
- Quarterly Cash from Investing Activities rose 14.06% year-over-year to -$5324.0 in Q2 2025, while the trailing twelve-month figure through Jan 2026 was -$5324.0 (up 94.22% YoY) and the FY2026 annual result came in at -$5324.0, up 94.22% from the prior year.
- Cash from Investing Activities improved to -$5324.0 in Q2 2025 per NTRB's latest filing, from -$46958.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at -$1272.0 in Q4 2022 and troughed at -$49137.0 in Q1 2024.
- A 5-year average of -$22144.8 and a median of -$17411.5 in 2021 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities surged 94.01% in 2023, then tumbled 390.24% in 2024.
- Over 5 years, Cash from Investing Activities stood at -$1992.0 in 2021, then surged by 36.14% to -$1272.0 in 2022, then tumbled by 106.29% to -$2624.0 in 2023, then slumped by 1689.56% to -$46958.0 in 2024, then soared by 88.66% to -$5324.0 in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$5324.0, -$46958.0, and -$38890.0 for Q2 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | NutriBand | 57.74 Mn | 53.73 Mn | 196,801.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2025 | -5,324.00 |
| Apr 30, 2025 | -5,324.00 |
| Oct 31, 2024 | -46,958.00 |
| Oct 31, 2024 | -46,958.00 |
| Jul 31, 2024 | -38,890.00 |
| Jul 31, 2024 | -38,890.00 |
| Apr 30, 2024 | -6,195.00 |
| Apr 30, 2024 | -6,195.00 |
| Jan 31, 2024 | -49,137.00 |
| Jan 31, 2024 | -49,137.00 |
| Apr 30, 2023 | -2,624.00 |
| Apr 30, 2023 | -2,624.00 |
| Jan 31, 2023 | -10,023.00 |
| Jan 31, 2023 | -10,023.00 |
| Oct 31, 2022 | -1,272.00 |
| Oct 31, 2022 | -1,272.00 |
| Jul 31, 2022 | -24,206.00 |
| Jul 31, 2022 | -24,206.00 |
| Apr 30, 2022 | -43,803.00 |
| Apr 30, 2022 | -43,803.00 |